Navigation Links
Encorium Group, Inc. Completes $1.6 Million Private Placement of Common Stock and Executes Warrant Exchange Agreement; Ends Discussions to Sell Encorium OY
Date:10/19/2009

positioned to win future contracts in the vaccine and oncology fields. As a result, the Company believes stockholder value will be maximized by moving ahead independently, while continuing to focus on clinical vaccine development.

Dr. Kai Lindevall, executive chairman stated, "We are very pleased that we were able to close this financing to shore up our balance sheet and provide the Company with additional working capital. Our experience and capabilities in the vaccine field coupled with the recent new awards in this area demonstrate the long term potential we have to grow into a leading vaccine franchise with expertise in pre-clinical support, regulatory consultancy and strategic trial planning. We believe these developments will position us to move ahead independently and are in the best interest of all stockholders."

Of the 35,000,000 authorized capital stock of the Company, 26,325,383 shares of common stock will be issued and outstanding immediately following the closing.

The shares of common stock issued in connection with the above transactions have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration under the Securities Act and applicable state securities laws or an applicable exemption from those registration requirements. The Exchange Shares will be immediately freely transferable pursuant to Rule 144 of the Act since the Investors are not affiliates of the Company and since the Investors will be deemed to have held the Exchange Shares for greater than 6 months pursuant to (d)(3)(ii) of Rule 144. For additional information on the transactions described below, please see our Current Report on Form 8-K filed with the SEC on October 19, 2009, which is available on the SEC website at www.sec.gov

Quarterly Results and Conference Call

Financial results for the third q
'/>"/>

SOURCE Encorium Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Encorium Group, Inc. Announces New Business Awards of $8.7 Million, Including Swine Flu (Influenza A H1N1 virus) Vaccine Trial Win;
2. Encorium Announces Receipt of Letters from Nasdaq Regarding its Second Quarter 2009 Form 10-Q Filing
3. Encorium Reports Second Quarter 2009 Financial Results
4. Encorium Group Completes Sale of its U.S. Business to Pierrel Research USA; Announces Management Changes
5. Encorium Group Updates Expected Timeframe with Respect to the Sale of its U.S. Business
6. Professor Hanna Nohynek Joins Encorium as Head Consultant of its Clinical Vaccine Research Team
7. Encorium Named as Finalist for the Second Annual Vaccine Industry Excellence Award
8. Encorium Group Signs Approximately $2.0 Million of New Business Contracts
9. Encorium Group Signs $3.1 Million of New Business Contracts Including an Extension of a Current U.S. Oncology Clinical Trial with a Major Pharmaceutical Company
10. Encorium Announces Receipt of Letter from Nasdaq Regarding its Third Quarter 2008 Form 10-Q Filing
11. Encorium Reports Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Aug. 20, 2014 /PRNewswire-iReach/ -- A case study ... between the school,s bioengineering department and the Intel® ... Intel® Software Academic Program, UCSD,s research focuses on ... human body.  Photo - ... the work of Dr. Todd P. Coleman ...
(Date:8/19/2014)... Piscataway, NJ (PRWEB) August 20, 2014 ... engineering and regenerative medicine is an inadequate vascular ... engineered constructs and decellularized tissues is critical for ... Researchers have attempted to mitigate deficiencies in vascularization ... including adding scaffold bioactivity, optimizing scaffold design and ...
(Date:8/19/2014)... 2014 Cellgen Diagnostics ... to fund a corporate lab for its genetic-based ... development is a critical component in the move ... the implementation of personalized medicine – a more ... , Indiegogo contributions will support Cellgen’s intent to ...
(Date:8/19/2014)... , Aug. 19, 2014 ... addition of the "Spectroscopy Equipment and ... report to their offering. ... Spectroscopy Equipment and Accessories in US$ Thousands ... (UV-Vis spectrophotometers, Raman Spectrometers, NMR-EPR Spectrometers, Near ...
Breaking Biology Technology:Intel and University of San Diego Bioengineering Department Release Case Study on Health Sciences Research 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3Global Spectroscopy Equipment and Accessories - Strategic Business Report 2014 2
... 13, 2010 ... ... var shortURL = ... so we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; ...
... sunscreens when they are exposed to sunlight? And how is ... has been the subject of research at the University of ... at the upcoming dermatologist conference in Gothenburg. A growing ... habits have brought an increase in the number of cases ...
... Beta-Pro LLC, announced today that it has ... pharmaceutical drug discovery and research institutes in the ... company now manages extensive laboratory facilities in the ...   "Beta-Pro has already established a ...
Cached Biology Technology:Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco 2Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco 3Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco 4Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco 5Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco 6Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco 7Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco 8Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco 9So that's why we're allergic to sun creams 2Beta-Pro Expands Operations to Meet Demands for Human Cells in Hepatocyte Drug Discovery Market 2
(Date:8/20/2014)... salty aroma of sunscreen and seawater signals a relaxing ... that the idyllic beach vacation comes with an environmental ... into the sea, they can become toxic to some ... course for many other marine animals. Their study appears ... . , Antonio Tovar-Sanchez and David Snchez-Quiles point out ...
(Date:8/20/2014)... A new gene therapy developed by researchers at the ... to protect mice from a life-threatening heart condition caused ... therapeutic avenue," said Yi Lai, Ph.D., the leading author ... MU School of Medicine,s Department of Molecular Microbiology and ... hope this could lead to a treatment for people ...
(Date:8/20/2014)... DENVER , Aug. 20, 2014  The ... take place in Tampa, Florida ... interactive sessions with Steven Rahman, Director, Technology and Strategy ... Sector at Experian. The theme of this year,s ... and Privacy. "Biometrics UnPlugged: Mobility ...
Breaking Biology News(10 mins):Gene therapy protects mice from lethal heart condition, MU researchers find 2Biometrics UnPlugged: Mobility at the Crossroads of Commerce & Privacy to Feature Interactive Sessions with Samsung and Experian 2
... Athens, Ga. For more than a century, the ... it comes to human health. As it turns out, X-rays ... and a new approach -- just published by researchers at ... can learn using the technique. One of the primary ...
... a recent study by the University of Santiago de Compostela ... unexpected increase in hydrocarbon levels along the coast of Galicia ... years by works to remove the wreck, pollution levels began ... numerous forest fires., On 19th November 2002 the oil tanker ...
... only become a science in the past 25 years, ... with widespread international collaboration, broad disciplinary composition and wide ... National Laboratory and Indiana University. The findings, published today ... Sciences, were assembled from a review of 20,000 ...
Cached Biology News:New strategy could lead to dose reduction in X-ray imaging 2New strategy could lead to dose reduction in X-ray imaging 3Hydrocarbon pollution along the coast of Galicia shot up five years after the Prestige oil spill 2After 25 years, sustainability is a growing science that's here to stay 2
... At the forefront of Agilent analytical ... Built-in local area networking (LAN) allows you ... sites--for fast and informed decision making. Just ... has all the flexibility and performance needed ...
... Inc.'s CP-4900 is a rugged, ... delivers the information you need ... the composition of gas mixtures ... micro-Gas Chromatograph generates more data ...
... GC system combines world-class performance hardware, Cerity ... Agilents world-renowned support and columns, as well ... combination that lets you reach uncompromising results ... dependable data. The Agilent 6820 GC system ...
... Peroxisome Proliferator-Activated Receptor-gamma (PPARGamma) Competitor ... and efficient method for studying ... using fluorescence polarization (FP). The ... domain (PPARGamma-LBD) with an N-terminal ...
Biology Products: